[go: up one dir, main page]

MX2023004074A - Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica. - Google Patents

Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica.

Info

Publication number
MX2023004074A
MX2023004074A MX2023004074A MX2023004074A MX2023004074A MX 2023004074 A MX2023004074 A MX 2023004074A MX 2023004074 A MX2023004074 A MX 2023004074A MX 2023004074 A MX2023004074 A MX 2023004074A MX 2023004074 A MX2023004074 A MX 2023004074A
Authority
MX
Mexico
Prior art keywords
modulators
cystic fibrosis
transmembrane conductance
regulator
pharmaceutical compositions
Prior art date
Application number
MX2023004074A
Other languages
English (en)
Inventor
Joe A Tran
Mark Thomas Miller
Vijayalaksmi Arumugam
Jinglan Zhou
Bryan A Frieman
Lev Tyler Dewey Fanning
Jason Mccartney
Lino Valdez
Alina Silina
Paul Krenitsky
Prasuna Paraselli
Thomas Cleveland
Timothy Richard Coon
Haripada Khatuya
Vito Melillo
Ruah Sara Sabina Hadida
Alexander Russell Abela
Johnny Uy
Corey Don Anderson
Anton V Gulevich
Fabrice Pierre
Sunny Abraham
Jaclyn Chau
Jeremy Clemens
Timothy A Dwight
Yoshihiro Ishihara
Peter Grootenhuis
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MX2023004074A publication Critical patent/MX2023004074A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Amplifiers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta descripción proporciona moduladores del regulador de la conductancia transmembrana de la fibrosis quística (CFTR) que tiene la estructura central: composiciones farmacéuticas que contienen al menos un modulador de este tipo, métodos de tratamiento de enfermedades mediadas por CFTR, que incluyen fibrosis quística, mediante el uso de tales moduladores y composiciones farmacéuticas, composiciones farmacéuticas combinadas y terapias combinadas, y procesos y productos intermediarios para la fabricación de tales moduladores. (ver Fórmula).
MX2023004074A 2020-10-07 2021-10-06 Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica. MX2023004074A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063088935P 2020-10-07 2020-10-07
PCT/US2021/053860 WO2022076624A1 (en) 2020-10-07 2021-10-06 Modulators of cystic fibrosis transmembrane conductance regulator

Publications (1)

Publication Number Publication Date
MX2023004074A true MX2023004074A (es) 2023-07-05

Family

ID=78771139

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004074A MX2023004074A (es) 2020-10-07 2021-10-06 Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica.

Country Status (20)

Country Link
US (1) US20230382925A1 (es)
EP (1) EP4225764A1 (es)
JP (1) JP2023545081A (es)
KR (1) KR20230104618A (es)
CN (1) CN116783204A (es)
AR (1) AR123709A1 (es)
AU (1) AU2021358063A1 (es)
BR (1) BR112023006381A2 (es)
CA (1) CA3197857A1 (es)
CL (1) CL2023000984A1 (es)
CO (1) CO2023005734A2 (es)
CR (1) CR20230200A (es)
DO (1) DOP2023000066A (es)
EC (1) ECSP23032164A (es)
IL (1) IL301755A (es)
MX (1) MX2023004074A (es)
PE (1) PE20231185A1 (es)
TW (1) TW202233635A (es)
UY (1) UY39460A (es)
WO (1) WO2022076624A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY38630A (es) * 2019-04-03 2020-10-30 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US11584761B2 (en) 2019-08-14 2023-02-21 Vertex Pharmaceuticals Incorporated Process of making CFTR modulators
EP4013760A1 (en) 2019-08-14 2022-06-22 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
EP4225765A2 (en) * 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US12324802B2 (en) 2020-11-18 2025-06-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
AU2021397294A1 (en) 2020-12-10 2023-07-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
IL314449A (en) 2022-02-03 2024-09-01 Vertex Pharma Methods of treatment for cystic fibrosis
KR20240155228A (ko) 2022-02-03 2024-10-28 버텍스 파마슈티칼스 인코포레이티드 (6a,12a)-17-아미노-12-메틸-6,15-비스(트리플루오로메틸)-13,19-디옥사-3,4,18-트리아자트리시클로[12.3.1.12,5]노나데카-1(18),2,4,14,16-펜타엔-6-올의 결정질 형태를 제조하는 방법
GEAP202516620A (en) * 2022-04-06 2025-04-10 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
CN119947720A (zh) 2022-05-16 2025-05-06 弗特克斯药品有限公司 治疗囊性纤维化的方法
CN119907667A (zh) 2022-09-15 2025-04-29 爱杜西亚药品有限公司 大环cftr调节剂与cftr校正剂和/或cftr增效剂的组合
CN119894906A (zh) 2022-09-15 2025-04-25 爱杜西亚药品有限公司 大环cftr调节剂
TW202421636A (zh) 2022-09-15 2024-06-01 瑞士商愛杜西亞製藥有限公司 (3S,7S,10R,13R)-13-苄基-20-氟-7-異丁基-N-(2-(3-甲氧基-1,2,4-㗁二唑-5-基)乙基)-6,9-二甲基-1,5,8,11-四側氧基-10-(2,2,2-三氟乙基)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-十四氫-[1]㗁[4,7,10,14]四氮雜環十七烷并[16,17-f]喹啉-3-甲醯胺的晶型
WO2025186214A1 (en) 2024-03-05 2025-09-12 Idorsia Pharmaceuticals Ltd Macrocyclic cftr modulators

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ587549A (en) 2004-06-24 2012-10-26 Vertex Pharma 6-Amino-indole derivatives and processes for their preparation
KR101331768B1 (ko) 2005-11-08 2013-11-22 버텍스 파마슈티칼스 인코포레이티드 Ａｔｐ 결합 카세트 수송체의 헤테로사이클릭 조정제
CA2635581C (en) 2005-12-28 2017-02-28 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
JP2009536969A (ja) 2006-05-12 2009-10-22 バーテックス ファーマシューティカルズ インコーポレイテッド Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミド組成物
DK2639223T3 (en) 2007-12-07 2017-06-19 Vertex Pharma Process for Preparation of Cycloalkylcarboxiamido-pyridine Benzoic Acids
HRP20170241T2 (hr) 2007-12-07 2023-03-17 Vertex Pharmaceuticals Incorporated Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline
ES2660143T3 (es) 2008-08-13 2018-03-21 Vertex Pharmaceuticals Incorporated Composición farmacéutica de N-[2,4-Bis(1,1-dimetiletilo)-5-hidroxifenilo]-1,4-dihidro-4-oxoquinolina-3carboxamida y administración de la misma
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US8716338B2 (en) 2008-09-29 2014-05-06 Vertex Pharmaceuticals Incorporated Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
BRPI0823228B8 (pt) 2008-11-06 2021-05-25 Vertex Pharmaceuticals Incorporarted moduladores de cassete de ligação a atp
PL2408750T3 (pl) 2009-03-20 2016-02-29 Vertex Pharma Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy
NZ700556A (en) 2010-03-25 2016-04-29 Vertex Pharma Solid forms of (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
CN102811938B (zh) 2010-04-09 2016-10-12 艾克索仿生技术公司 外骨骼负载处理系统及其使用方法
NZ603042A (en) 2010-04-22 2015-02-27 Vertex Pharma Pharmaceutical compositions comprising cftr modulators and administrations thereof
CA2797118C (en) 2010-04-22 2021-03-30 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
US20120064157A1 (en) 2010-08-27 2012-03-15 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
ES2758028T3 (es) 2011-05-18 2020-05-04 Vertex Pharmaceuticals Europe Ltd Derivados deuterados de ivacaftor
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
AU2013226076B2 (en) 2012-02-27 2017-11-16 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administration thereof
EP2872122A1 (en) 2012-07-16 2015-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
SMT202500078T1 (it) 2012-11-02 2025-03-12 Vertex Pharma Composizioni farmaceutiche per il trattamento di malattie mediate da cftr
WO2014078842A1 (en) 2012-11-19 2014-05-22 Concert Pharmaceuticals, Inc. Deuterated cftr potentiators
RS62140B1 (sr) 2014-04-15 2021-08-31 Vertex Pharma Farmaceutske kompozicije za lečenje bolesti posredovanih transmembranskim regulatorom provodljivosti cistične fibroze
IL313498A (en) * 2014-10-06 2024-08-01 Vertex Pharma Modulators of the cystic fibrosis transmembrane conductance regulator
MX388470B (es) 2015-09-21 2025-03-20 Vertex Pharmaceuticals Europe Ltd Administración de potenciadores de regulador de la conductancia transmembrana de fibrosis quística (cftr) deuterados.
HRP20211683T1 (hr) * 2016-09-30 2022-03-04 Vertex Pharmaceuticals Incorporated Modulator transmembranskog regulatora provodljivosti cistične fibroze, farmaceutski pripravci, postupci liječenja, i postupak za pripravu modulatora
WO2018080591A1 (en) 2016-10-27 2018-05-03 Vertex Pharmaceuticals (Europe) Limited Methods of treatment with deuterated cftr potentiators
US11465985B2 (en) * 2017-12-08 2022-10-11 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
LT3752510T (lt) * 2018-02-15 2023-04-11 Vertex Pharmaceuticals Incorporated Makrocikliniai junginiai kaip cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatoriai, jų farmacinės kompozicijos, jų panaudojimas cistinės fibrozės gydymui ir jų gamybos būdas
EP3898621A1 (en) * 2018-12-21 2021-10-27 Novartis AG Macrocyclic compounds and their use in the treatment of disease
UY38630A (es) * 2019-04-03 2020-10-30 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
EP4013760A1 (en) * 2019-08-14 2022-06-22 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
IL314449A (en) * 2022-02-03 2024-09-01 Vertex Pharma Methods of treatment for cystic fibrosis

Also Published As

Publication number Publication date
PE20231185A1 (es) 2023-08-11
CN116783204A (zh) 2023-09-19
TW202233635A (zh) 2022-09-01
JP2023545081A (ja) 2023-10-26
CR20230200A (es) 2023-07-13
DOP2023000066A (es) 2023-07-09
AU2021358063A1 (en) 2023-05-18
CL2023000984A1 (es) 2023-11-24
IL301755A (en) 2023-05-01
BR112023006381A2 (pt) 2023-09-26
US20230382925A1 (en) 2023-11-30
KR20230104618A (ko) 2023-07-10
CO2023005734A2 (es) 2023-07-21
AU2021358063A9 (en) 2025-03-13
UY39460A (es) 2022-05-31
AR123709A1 (es) 2023-01-04
EP4225764A1 (en) 2023-08-16
ECSP23032164A (es) 2023-06-30
WO2022076624A1 (en) 2022-04-14
CA3197857A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
MX2023004074A (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica.
MX2023004072A (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica.
MX2023004073A (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica.
MX2022001827A (es) Moduladores del regulador de conductancia transmembrana de la fibrosis quistica.
CL2023000375A1 (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
GEAP202415749A (en) Cystic fibrosis transmembrane conductance regulator modulating agents
MX2024012385A (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica
CR20210592A (es) Moduladores de la vía integrada del estrés
UY39455A (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
IL189178A0 (en) Thiazolyl derivatives and pharmaceutical compositions containing the same
BR112021014566A2 (pt) Moduladores de gpr35
MX2024012452A (es) Tratamiento combinado
HK40044905A (en) Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EA202191927A1 (ru) Модуляторы gpr35